RCM
KDNY

RA Capital Management’s Chinook Therapeutics, Inc. Common Stock KDNY Stock Holding History

RA Capital Management’s Portfolio KDNY Stock Details KDNY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q2 		– Sell
-1,000,000
Closed -$16.4M – 107
2022
Q1 		$16.4M Hold
1,000,000
– – 0.36% 58
2021
Q4 		$16.3M Buy
+1,000,000
New +$14.2M 0.29% 63

Other funds holding KDNY

SB
Samsara BioCapital Palo Alto, California $1.03B AUM 214.94% 1-Year Est. Return
FLSM
Frazier Life Sciences Management Palo Alto, California $3.89B AUM 201.1% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
OCA
Octagon Capital Advisors New York $904M AUM 737.04% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
SCM
Suvretta Capital Management New York $3.92B AUM 86.67% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

RA Capital Management's KDNY Position: Q2 2022 in Review

RA Capital Management sold out of Chinook Therapeutics, Inc. Common Stock (KDNY) in Q2 2022, closing a stake of 1,000,000 shares — an estimated $16.4M sold.

RA Capital Management first reported a position in KDNY in Q4 2021 and held it in 2 quarters. The position peaked at $16.4M in Q1 2022. 135 funds tracked by Wall St. Rank hold KDNY as of Q2 2022.

  • RA Capital Management reported no remaining Chinook Therapeutics, Inc. Common Stock position as of Q2 2022 after selling out during the quarter.
  • RA Capital Management sold 1,000,000 Chinook Therapeutics, Inc. Common Stock shares in Q2 2022, an estimated $16.4M.
  • RA Capital Management first reported a position in Chinook Therapeutics, Inc. Common Stock in Q4 2021 and held it in 2 quarters.
  • RA Capital Management's Chinook Therapeutics, Inc. Common Stock position peaked at $16.4M in Q1 2022.
  • 135 funds tracked by Wall St. Rank held Chinook Therapeutics, Inc. Common Stock as of Q2 2022.

Based on RA Capital Management's 13F filing for Q2 2022, filed 15 Aug 2022.